Unverified50% confidenceFactExact time
Current OpDis-PS research is still limited to simulated data, and validation on real clinical data is the key next step.
1
Sources
50%
Confidence
Short-term (~14 days)
Relevance
11/16/2026
First Seen
Valid until: 11/30/2026
Sources
Related Entities
Related Claims
UnverifiedThe paper has so far validated clustering performance only on public datasets, and issues in real biomedical data such as missing values, modality differences, and悬殊 sample sizes across institutions still await further testing.67% similarUnverifiedAs a newly released model, NV-Reason-CT's real-world clinical performance still needs to be validated on actual data from multiple centers and disease types.66% similarUnverifiedThe study evaluated large models using real clinical cases rather than standardized exam questions in order to reflect the capability boundaries of models in practical applications.65% similarUnverifiedThe study has limitations: the calibration advantage of synthetic data is unstable, clinical plausibility still requires physician involvement to improve, and the external generalizability to private cohorts awaits further validation.65% similarUnverified"Entering clinical trials" does not equal "proven effective"; the current information only supports the judgment that GLP-1 drugs are "being explored" in the heart failure, addiction, and aging directions.64% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1174279API
curl https://kongchang.com/api/v1/knowledge/claims/1174279MCP
get_claim(id=1174279)